Title:Amyloid Beta 1-42 Inhibits Entorhinal Cortex Activity in the Beta-Gamma Range: Role of GSK-3
Volume: 9
Issue: 7
Author(s): Fernando Pena-Ortega, Angeles Solis-Cisneros, Benito Ordaz, Hugo Balleza-Tapia and Juan Javier Lopez-Guerrero
Affiliation:
Keywords:
Alzheimer’s disease, gamma oscillations, network activity, amyloid beta protein, GSK-3, lithium, depression.
Abstract: Oscillatory activity in the entorhinal cortex has been associated with several cognitive functions. Accordingly,
Alzheimer Disease-associated cognitive decline has been related to amyloid beta-induced disturbances in several of these
oscillatory patterns. We have previously shown that acute application of amyloid beta inhibits the generation of slowfrequency
oscillations (7-20 Hz). In contrast, alterations in faster oscillations recorded in Alzheimer Disease-transgenic
mice that over-express amyloid beta have been controversial. Since transgenic mice may produce complex responses due
to compensatory mechanisms, we tested the effect of acute application of amyloid beta on fast oscillations (beta-gamma
bursts) generated by entorhinal cortex slices in vitro in a Mg2+-free solution. We also explored the participation of the enzyme
glycogen synthase kinase 3 (GSK-3) in this effect. Our results show that bath application of a clinically relevant
concentration of amyloid beta (10 nM) activates GSK-3 and reduces the power of beta-gamma bursts in the entorhinal
cortex. The reduction of beta-gamma bursts by amyloid beta is blocked by inhibiting GSK-3 either with lithium or with
SB 216763. Our results suggest that amyloid beta-induced inhibition of entorhinal cortex beta-gamma activity involves
GSK-3 activation, which may provide a molecular mechanism for amyloid beta-induced neural network disruption and
support the use of GSK-3 inhibitors to treat Alzheimer Disease.
